The cheapest way to buy a branded GLP-1 without insurance in the United States is the manufacturer’s own direct pharmacy rather than a retail counter. As of late September 2026 the published self-pay floors are $149 a month for the Wegovy pill at its starting dose, $299 a month for the 2.5 mg Zepbound vial and $349 a month for standard Wegovy or Ozempic doses, against list prices above $1,000.
The catch is that none of those numbers is the price of a year of treatment. Every programme prices by dose, and the dose goes up during the first few months, so the figure that matters is what the maintenance dose costs rather than the starter tier.
Disclosure: this article is published by GLP1WeightLossCalculator.com, which makes the weight loss calculator linked below. It has no commercial relationship with any manufacturer or pharmacy named here, and every price is quoted from the programme’s own published price guide.
What each option costs today
Prices checked on 29 September 2026. These programmes reprice frequently, and several tiers carry expiry dates, so treat this as a snapshot and check the current figure before committing.
| Option | What it is | Published self-pay price | Conditions |
|---|---|---|---|
| Wegovy pill (oral semaglutide) | Daily tablet, weight management | From $149/month at the starting dose; $299/month at 9 mg and 25 mg | NovoCare Pharmacy; introductory tiers carry end dates |
| Zepbound single-dose vials | Weekly tirzepatide, drawn with a syringe | $299 (2.5 mg), $399 (5 mg), $449 (7.5 to 15 mg) | LillyDirect; the $449 tier requires a refill within 45 days, otherwise $499 to $699 |
| Wegovy injection | Weekly semaglutide, weight management | $349/month for 0.25 to 2.4 mg; $399 for the 7.2 mg version | NovoCare Pharmacy; $199 introductory fills for new patients at the two lowest doses |
| Ozempic | Weekly semaglutide, type 2 diabetes | $349/month for 0.25, 0.5 and 1 mg; $499 for 2 mg | NovoCare Pharmacy; diabetes indication |
| Generic liraglutide | Daily injection, the only generic GLP-1 | Roughly $230 to $400/month with a discount card | Pharmacy and card dependent, so quotes vary widely |
List price is not the price
The number that gets quoted in news coverage is the list price, which in September 2026 is around $1,349 a month for Wegovy and around $1,060 for Zepbound. Almost nobody pays it. It is the figure before insurance, rebates and the manufacturer programmes, and it exists mainly as the starting point for negotiations you are not part of.
What replaced it for uninsured buyers is direct-to-patient pharmacy. Both Novo Nordisk and Eli Lilly now sell their own products at a published cash price, which is why the gap between "without insurance" and "with insurance but a high deductible" has narrowed to the point where the self-pay route is sometimes the cheaper of the two.
The manufacturer programmes, in detail
NovoCare Pharmacy: semaglutide
Novo Nordisk sells Wegovy and Ozempic direct at a flat monthly price per dose tier, with home delivery or pickup at a retail partner. New Wegovy patients are offered two introductory fills at the 0.25 mg and 0.5 mg doses before the standard price applies. The Wegovy pill, licensed in January 2026, sits at the bottom of the range at its starting dose and rises to $299 at the two highest doses.
One exclusion catches a lot of people. Manufacturer savings offers are not available to anyone with Medicare, Medicaid, TRICARE or VA benefits, because federal anti-kickback rules prohibit it. Being enrolled in one of those programmes does not let you opt out of it for this purpose.
LillyDirect: tirzepatide
Lilly sells Zepbound as single-dose vials rather than pens, which is the main reason the price is lower. The vial tiers run from $299 at 2.5 mg to $449 for everything from 7.5 mg upward, and that top tier is conditional: the refill has to arrive within 45 days of the previous one, otherwise the price reverts to $499 for 7.5 mg and $699 for 10 mg and above.
Vials also shift a step onto the patient. A pen meters its own dose, while a vial has to be drawn into a syringe, which introduces the unit arithmetic that produces most reported GLP-1 dosing errors. Our mg to units explainer covers the formula and the failure modes, and there is a worked example for the 2.5 mg tirzepatide dose specifically.
Generic liraglutide, the one genuine generic
Liraglutide is the only GLP-1 with generic competition. Generic Victoza arrived first for type 2 diabetes, and a generic of Saxenda, the weight management version, followed in August 2025. Cash prices with a discount card land in the low hundreds, which can undercut every branded programme above.
Two things make it a different proposition rather than simply a cheaper one. It is a daily injection rather than a weekly one, and its trial results are smaller than the semaglutide and tirzepatide figures people arrive with. Cheapest per month and cheapest per unit of effect are not the same question.
The compounded market has narrowed sharply
Compounded semaglutide and tirzepatide were the cheapest option in the United States for roughly two years, on a legal pathway that only exists while a drug is in shortage. That pathway has closed. The FDA removed tirzepatide from its shortage list in December 2024 and semaglutide in February 2025, and in April 2026 proposed permanently excluding semaglutide, tirzepatide and liraglutide from the bulk substances list that large outsourcing facilities compound from. A wave of warning letters to telehealth firms and compounding pharmacies followed in March 2026.
Patient-specific compounding under a 503A pharmacy licence still exists in narrow circumstances, such as a documented allergy to an excipient in the approved product. What has gone is the broad, shortage-driven supply that the low advertised prices were built on. Anything still marketed at those prices deserves a hard look at who is making it.
The safety record of that market is also on the public record. Poison control case series document ten-fold overdoses traced to confusion between millilitres, units and milligrams on compounded vials (PMID 37392810, PMID 38470137). Those errors are a property of the packaging and the arithmetic, not of the molecule.
Budget for the dose you will be on, not the one you start on
Every programme here prices by dose, and the labelled schedules climb for the first few months. A Zepbound budget built on the 2.5 mg tier understates a 10 mg year by $150 a month. A Wegovy budget is flatter, since the injection is one price across the whole 0.25 mg to 2.4 mg range, but the 7.2 mg version is priced above it.
The other variable is duration. GLP-1 treatment for weight is generally ongoing rather than a fixed course: in the STEP 1 trial extension, participants regained about two thirds of their loss in the year after stopping. A monthly price is the honest unit of comparison only if you multiply it by the number of months you expect to be paying it.
Work out what a year of treatment is buying you
See what the published trial averages work out to in pounds from your own starting weight.
FAQ
What is the cheapest GLP-1 you can get without insurance?
Among branded products, the lowest published self-pay prices as of late September 2026 are the Wegovy pill from $149 a month at its starting dose and the 2.5 mg Zepbound vial at $299 a month. Generic liraglutide with a discount card can be lower still, but it is a daily injection with a different evidence base.
Is Zepbound cheaper than Wegovy without insurance?
At the lowest doses, yes. LillyDirect lists the 2.5 mg Zepbound vial at $299 a month against $349 for standard Wegovy injection doses. From 7.5 mg upward Zepbound is $449 a month when refilled within 45 days, which puts it above Wegovy.
Do the manufacturer savings programmes work with Medicare?
No. Manufacturer savings offers are closed to people with Medicare, Medicaid, TRICARE or VA benefits under federal anti-kickback rules. That applies whether or not the benefit covers the drug itself.
Is compounded semaglutide still available?
Only in narrow, patient-specific circumstances. The FDA declared the semaglutide shortage resolved in February 2025, which ended the broad compounding pathway, proposed in April 2026 to exclude it permanently from the 503B bulks list, and issued a large wave of warning letters in March 2026.
Why are GLP-1 list prices so much higher than the cash prices?
List price is set before rebates and discounts and is the basis for negotiation with insurers, not a retail price. The manufacturer direct pharmacies bypass that chain and publish a single cash figure, which is why the two numbers differ by roughly a factor of three.
Does the cheapest option stay cheapest as the dose goes up?
Usually not. Zepbound vials move from $299 to $449 a month across the dose range, and the Wegovy pill from $149 to $299. The Wegovy injection is the flattest of the programmes at $349 across its standard doses.
Sources
- NovoCare Pharmacy published self-pay price guides for Wegovy, the Wegovy pill and Ozempic, checked 29 September 2026.
- LillyDirect published self-pay pricing for Zepbound single-dose vials, checked 29 September 2026.
- FDA. Clarification of policies for compounders as national GLP-1 supply begins to stabilize. Drug alerts and statements, 2025.
- FDA proposed rule on the 503B bulk drug substances list covering semaglutide, tirzepatide and liraglutide, April 2026.
- Cohen IV, Rivas VM, Guo J, et al. Administration errors of compounded semaglutide reported to a poison control center: case series. J Am Pharm Assoc. 2023. PMID: 37392810
- Simpson SJ, Nguyen A, Kang AM. Challenges with glucagon-like peptide-1 (GLP-1) agonist initiation: a case series of semaglutide overdose administration errors. Clin Toxicol (Phila). 2024;62(2):113-116. PMID: 38470137
- Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. PMID: 35441470
This article is for information only and is not medical advice. Dosing, suitability and any change to treatment are decisions for your prescriber.